Arcutis Q4 2023 revenue $13.5M (+357% YoY), net loss $66.3M; ZORYVE foam launched

Arcutis Biotherapeutics, Inc.

2023-FY EPS reported -$3.78 revenue$59,606,000

Q4 net product revenue $13.5M vs $3.0M Q4 2022, driven by 67% sequential demand growth and GTN improvement.
Full-year 2023 total revenue $59.6M (incl. $30.4M Huadong upfront); net loss $262.1M ($3.78/share).
R&D expenses fell 39% to $110.6M; cash & securities $272.8M as of Dec 31, 2023.
FDA approved ZORYVE foam for seborrheic dermatitis Dec 2023; launched Jan 2024.
PDUFA target date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcutis Biotherapeutics, Inc. reported the quarter ended December 31, 2023 results: revenue $13.5 million.

Period: the quarter ended December 31, 2023
Revenue: $13.5 million
Result: reported results

Exact text from the filing

--- Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Q4 net product revenues for ZORYVE® (roflumilast) cream 0.3% were $13.5 million, a 357% increase compared to the fourth quarter of 2022 and a 67% increase compared to the third quarter of 2023; driven by sequential improvement in gross-to-net (GTN) in the

View on SEC.gov

Browse all earnings releases →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-24-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.